KR20080043384A - 경피적 활성 성분 전달 수단 - Google Patents

경피적 활성 성분 전달 수단 Download PDF

Info

Publication number
KR20080043384A
KR20080043384A KR1020087007977A KR20087007977A KR20080043384A KR 20080043384 A KR20080043384 A KR 20080043384A KR 1020087007977 A KR1020087007977 A KR 1020087007977A KR 20087007977 A KR20087007977 A KR 20087007977A KR 20080043384 A KR20080043384 A KR 20080043384A
Authority
KR
South Korea
Prior art keywords
digoxin
furosemide
skin
release
drug
Prior art date
Application number
KR1020087007977A
Other languages
English (en)
Korean (ko)
Inventor
이안 스튜어트 파르도
크리스토퍼 하트레이
Original Assignee
핸더슨 몰리 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 핸더슨 몰리 피엘씨 filed Critical 핸더슨 몰리 피엘씨
Publication of KR20080043384A publication Critical patent/KR20080043384A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087007977A 2005-09-02 2006-08-22 경피적 활성 성분 전달 수단 KR20080043384A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517838.9A GB0517838D0 (en) 2005-09-02 2005-09-02 Transdermal active principle delivery means
GB0517838.9 2005-09-02

Publications (1)

Publication Number Publication Date
KR20080043384A true KR20080043384A (ko) 2008-05-16

Family

ID=35220717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087007977A KR20080043384A (ko) 2005-09-02 2006-08-22 경피적 활성 성분 전달 수단

Country Status (9)

Country Link
US (1) US20090074845A1 (fr)
EP (1) EP1968611A2 (fr)
JP (1) JP2009508814A (fr)
KR (1) KR20080043384A (fr)
AU (1) AU2006286367A1 (fr)
CA (1) CA2621200A1 (fr)
GB (1) GB0517838D0 (fr)
MX (1) MX2008003091A (fr)
WO (1) WO2007026124A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2441011A (en) * 2006-08-18 2008-02-20 Henderson Morley Plc Pharmaceutical composition for the treatment of neuropathic pain
WO2009103932A1 (fr) * 2008-02-19 2009-08-27 Henderson Morley Plc Utilisation d’un glycoside cardiaque et/ou d’un diurétique pour le traitement de la douleur neuropathique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139127A1 (fr) * 1983-08-22 1985-05-02 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Dispositif pour la délivrance transdermale de médicaments et sa fabrication
DE3617824A1 (de) * 1986-05-27 1987-12-03 Hoechst Ag Zusammensetzung fuer transdermale therapeutische systeme von schleifendiuretika
US5750136A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
DE4001034A1 (de) * 1990-01-16 1991-07-18 Eberhard Landau Pflaster fuer die behandlung von warzen
JPH03240732A (ja) * 1990-02-14 1991-10-28 Yasuo Tanaka 抗ウイルス剤
US5476664A (en) * 1994-04-15 1995-12-19 Leonard Bloom Treatment of warts using anthralins and occlusion
US20010051182A1 (en) * 1996-09-20 2001-12-13 Hopp Robert B. Skin patch for use in contact immunotherapy
GB2355192A (en) * 1999-10-15 2001-04-18 Henderson Morley Res & Dev Ltd Anti-viral treatment
AU780261B2 (en) * 1999-10-29 2005-03-10 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
CN1414863A (zh) * 1999-12-30 2003-04-30 亨德森莫利研究和开发有限公司 Dna病毒感染的治疗
GB2376628B (en) * 2001-06-19 2005-06-08 Henderson Morley Res & Dev Ltd Treatment of DNA viral infections in cats
AU2001287907A1 (en) * 2000-09-21 2002-04-02 Henderson Morley Research And Development Limited Diuretic or sulphonylurea for use in antiviral treatment
WO2003103696A1 (fr) * 2002-06-06 2003-12-18 Charles Laudadio Glucosides cardiaques pour le traitement des douleurs et des spasmes musculaires
GB2441011A (en) * 2006-08-18 2008-02-20 Henderson Morley Plc Pharmaceutical composition for the treatment of neuropathic pain

Also Published As

Publication number Publication date
JP2009508814A (ja) 2009-03-05
WO2007026124A3 (fr) 2008-09-25
GB0517838D0 (en) 2005-10-12
EP1968611A2 (fr) 2008-09-17
WO2007026124A2 (fr) 2007-03-08
MX2008003091A (es) 2009-02-25
AU2006286367A1 (en) 2007-03-08
CA2621200A1 (fr) 2007-03-08
US20090074845A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
Shidhaye et al. Buccal drug delivery of pravastatin sodium
RU2465003C2 (ru) Местное нанесение и препараты эритропоэтина для заживления кожных ран
RU2764443C2 (ru) Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен
CN109310646A (zh) 增强递送的肾上腺素组合物
CN109310647A (zh) 具有增强渗透的药物组合物
KR20050056942A (ko) 로티고틴 투여를 위한 향상된 경피 송달 시스템
Lu et al. Preparation and characterization of a metered dose transdermal spray for testosterone
EP1267884B1 (fr) Compositions pouvant etre utilisees comme promoteurs de penetration dans des formulations transdermiques pour des ingredients a forte activite lipophile
JP4624978B2 (ja) 血小板血症治療用製剤および治療方法
KR20080042164A (ko) 국소형 제형
KR20050025638A (ko) 향상된 경피 송달 시스템
Gimeno et al. Transbuccal delivery of doxepin: studies on permeation and histological investigation
KR20080043384A (ko) 경피적 활성 성분 전달 수단
JP2008534474A (ja) 経皮パッチ
JP2023506538A (ja) アゴメラチンを含有する経皮治療システム
Assaf et al. Design and evaluation of transdermal delivery system containing tamsulosin hydrochloride
Iman et al. Formulation and stability study of chlorpheniramine maleate transdermal patch
JP6345120B2 (ja) 経皮ホルモン送達
WO2009103932A1 (fr) Utilisation d’un glycoside cardiaque et/ou d’un diurétique pour le traitement de la douleur neuropathique
GB2441011A (en) Pharmaceutical composition for the treatment of neuropathic pain
Samyuktha Metta Development and Evaluation of a Novel Transungual Formulation (Nail Patch) for the Treatment of Onychomycosis
ES2309107T3 (es) Dispositivo y metodos transdermicos para felodipina.
Al-Jarsha et al. A Review on Film Forming Drug Delivery Systems
Anuroop et al. NEWER TRENDS IN FILM FORMING SYSTEMS FOR TOPICAL AND TRANSDERMAL DRUG DELIVERY
Vora Formulation and Enhancement Strategies for Decontamination and Drug Delivery into Healthy and Diseased Skin

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid